Bannerbild German Brest Group - Forschung

Übersicht über Kongressbeiträge von 2017

Mitglieder der German Breast Group präsentierten im Jahr 2017 folgende Beiträge auf internationalen Kongressen:

ESMO, Madrid, Spain

Brandberg Y, Loibl S,. Foukakis T,. Johansson H, Gnant M,. Singer C.F, von Minckwitz G, Bengtsson N-O, Karlsson E, Mlineritsch B, Hellstro M,. Steger G, Carlsson L, Egle D, Greil R, Bergh J. CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial” Ann of Oncology 2017; Abstract nr 1422O, ESMO 2017, Madrid

Metzger O, Mandrekar S, Ciruelos E, Loibl S, Valagussa P, Demichele A.M, Lim E, Tripathy D,. Winer E, Huang C, Khoeler M, Carey L, Francis P, Miller K, Goel S, Goetz M.P, Prat A, Loi S. Krop I, Gianni L. PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer, Ann of Oncology 2017; Abstract nr 324TiP, ESMO 2017, Madrid

Dalvi T, Gelmon K.A, Dent R, Pegram M, Loibl S, Tazir Y, Milner A, Lewis J. BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC). Ann of Oncology 2017; Abstract nr 316TiP, ESMO 2017, Madrid

Criscitiello C, Bayar M.A, Curigliano G, Symmans F, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga J-Y, Denkert C, Loibl S, Sotiriou C, Michiels S, Andre´ F. A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracyclinebased neoadjuvant chemotherapy. Ann of Oncology 2017; Abstract nr 217O, ESMO 2017, Madrid

Mayer E.L,.DemicheleA.M, PfeilerG,. Barry W, Metzger O, Rastogi P, Symmans F, Burstein H.J, Miller K, Loibl S, Schmatloch S, Goulioti T, Zardavas D,. Fesl C, Koehler M, Bartlett C Huang, Huang X, Piccart M, E. Winer4, Gnant M. PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR1/HER2-early breast cancer. Ann of Oncology 2017; Abstract nr 215TiP, ESMO 2017, Madrid

Untch M,. Schneeweiss A, Salat C, Rezai M, Zahm D-M, Klare P,. Blohmer J-U, Tesch H, Khandan F, Fasching P.A.,Jackisch C, Nekljudova V, von Minckwitz G, Loibl SLong-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) Ann of Oncology 2017; Abstract nr 163PD, ESMO 2017; Madrid

von Minckwitz G, Ponomarova O, Morales S, Zhang N, Hanes V. Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer. Annals of Oncology 28 (Supplement 5), 2017, Abstract nr 151PD, ESMO 2017, Madrid
Delaloge S, Ye Y, Cella D, Buyse M, Chan A, Barrios C,. Holmes F A, Mansi J,. Iwata H, Ejlertsen B, Moy B, von Minckwitz G, Chia S, Gnant M, Smichkoska S, Ciceniene A, Moran S, Auerbach A.H, Fallowfield L,. Jimenez M M. Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER21 breast cancer (BC): longitudinal analyses from the phase III ExteNET trial. Annals of Oncology 28 (Supplement 5), 2017, Abstract nr 177P, ESMO 2017, Madrid

Jimenez M M,. Holmes F.A,. Ejlertsen B, Delaloge S.,. Moy, B,. Iwata H,. von Minckwitz G,. Chia S, Mansi J,. Barrios C, Gnant M, Tomasevic Z,. Denduluri N, Separovic R, Kim S-B, Jakobsen E.H, Bryce R.P, Xu F, Buyse M, Chan A. Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER21 breast cancer (BC): 5-year analysis of the phase III ExteNET trial. Annals of Oncology 28 (Supplement 5), 2017, Abstract nr 149O, ESMO 2017, Madrid

IMPAKT, Brussels, Belgium

Loibl S, Pfarr N, Weber K, Neunhöffer T, Villegas S, Stenzinger A, Furlanetto J, Aktas B, Budczies J, Marmé F, Kahmann L, Denkert C, Weichert W. Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls. Cancer Res 2017;77(4 Suppl):Abstract nr P2-03-09, IMAKT Brussels.

ASCO 2017, Chicago, USA

von Minckwitz G, Jennifer Procter M, De Azambuja E, Zardavas D, Knott A, Viale G,. Suter T M, Arahmani A, Rouchet N, Clark E, Benyunes M, Lang I, Levy C,. Yardley D A, Bines J,. Gelber R D,. Piccart-Gebhart M J, Baselga J. APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). J Clin Oncol 35, 2017 (suppl; abstr LBA500), ASCO 2017, Chicago

Golshan M, Loibl S, Huober J B, O'Shaughnessy J, Rugo H S, Wolmark N, McKee M D, Maag D, Sullivan D M, Giranda V L, Liu X, von Minckwitz G, Geyer C E, Sikov W M, ntch M. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). J Clin Oncol 35, 2017 (suppl; abstr 514), ASCO 2017, Chicago

Loibl S, Untch M, Burchardi N, Huober J B, Blohmer J U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Rezai M, Jackisch Ch, Schmitt W D, von Minckwitz G, Thomalla J, Kummel S, Rautenberg B, Fasching P A, Rhiem K, Denkert C, Schneeweiss A. A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol 35, 2017 (suppl; abstr 3062), ASCO 2017, Chicago

Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J B, Klare P, Kummel S, Untch M, Kast K, Jackisch Ch, Thomalla J, Heppner B I, Blohmer J U, Rezai M, Frank M, Nekljudova V, von Minckwitz G, Loibl S. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). J Clin Oncol 35, 2017 (suppl; abstr 518), ASCO 2017, Chicago

Martin M, Loibl S, Hyslop T, de la Haba-Rodriguez J, Aktas B, Cirrincione C, Eva Maria M, Mehta K, Barry W T, Morales S, Carey L A, Saenz J A G, Partridge A, Martinez N, Hahn O M, Winer E P, Guerrero A, Hudis C, Casas M, Dickler M N. Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. J Clin Oncol 35, 2017 (suppl; abstr 1012), ASCO 2017, Chicago

Kummel S, Holtschmidt J, Gerber B, von der Assen A, Heil J, Thill M, Krug D, Schem Ch, Denkert C, Lubitz J, Blohmer J U, Hötzeld M, Seither F, Nekljudova V, Schwidde I, Uhrhan K, von Minckwitz G, Rezai M, Loibl S, Kuehn T. Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial. J Clin Oncol 35, 2017 (suppl; abstr 555), ASCO 2017, Chicago

Bayar M-A, Criscitiello C, Curigliano G, Symmans W F, Desmedt Ch, Bonnefoi H R, Sinn B V, Pruneri G, Vicier C, Pierga J-Y, Denkert C, Loibl S, Sotiriou C, Michiels S, Andre F. A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 35, 2017 (suppl; abstr 575), ASCO 2017, Chicago

Anders C K, Murthy R K, Hamilton E P, Borges V F, Cameron D A, Carey L A, Müller V, Curigliano G, Gelmon K A, Hortobagyi G N, Krop I E, Loibl S, Pivot X B, Pegram M D, Slamon D J, Hurvitz S A, Tsai M L, Winer E P. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). J Clin Oncol 35, 2017 (suppl; abstr TPS1107), ASCO 2017, Chicago

Wroblewski M, Velthaus J-L, Bauer R, Müller V, Schem Ch, Fasching P A, Karn T, Fehm T N, Kühn T, Rack B K, Denkert C, Untch M, Kittel K, Janning M, Minner S, Sauter G, Bokemeyer C, von Minckwitz G, Loibl S, Loges S. Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b. J Clin Oncol 35, 2017 (suppl; abstr 11522), ASCO 2017, Chicago

Furlanetto J, Thode Ch, Bassy M, Denkert C, Hanusch C, Huober J B, Jackisch Ch, Kummel S, Schneeweiss A, Untch M, Fasching P A, Karn T, Marme F, van Mackelenbergh M, Müller V, Schem Ch, von Minckwitz G, Strik D, Nekljudova N, Loibl S. Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC). J Clin Oncol 35, 2017 (suppl; abstr 10068), ASCO 2017, Chicago

Liedtke C, Kolberg H-Ch, Kerschke L, Goerlich D, Bauerfeind I, Fehm T N, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Staebler A, von Minckwitz G, Loibl S, Untch M, Kuehn T. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients converting from cN+ to ycN0 through primary systemic therapy (PST). J Clin Oncol 35, 2017 (suppl; abstr 560), ASCO 2017, Chicago

Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting. J Clin Oncol 35, 2017 (suppl; abstr TPS1115), ASCO 2017, Chicago

Loibl S, Werutsky G, Nekljudova V, Seiler S, Blohmer J U, Denkert C, Hanusch C, Huober J B, Jackisch Ch, Kummel S, Schneeweiss A, Untch M, Rhiem K, Fasching P A, von Minckwitz G, Furlanetto J. Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: A pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials. J Clin Oncol 35, 2017 (suppl; abstr 571), ASCO 2017, Chicago

Colleoni M, Luo W, Karlsson P, Chirgwin J H, Aebi S P, Jerusalem G H M, Neven P, Hitre E, Graas M-P, Simoncini E, Kamby C, Thompson A M, Loibl S, Gavilá J, Kuroi K, Gnant M, Rabaglio-Poretti M, Regan M M, Coates A S, Goldhirsch A. SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC). J Clin Oncol 35, 2017 (suppl; abstr 503), ASCO 2017 Chicago

Rugo H S, Andre F, Rubovszky G, Kaufman B, Inoue K, Takahashi M, Shimizu S, Ciruelos E M, Campone M, Conte P F, Iwata H, Loibl S, Mayer I A, Juric D, Longin A-S, Mills D, Wilke C, Sellami D B. A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1. J Clin Oncol 35, 2017 (suppl; abstr TPS1111), ASCO 2017 Chicago

Geyer C. E, O'Shaughnessy J, Untch M, Sikov W, Rugo H. S, McKee M. D, Huober J B, Golshan M, Giranda V L, von Minckwitz G, Maag D, Sullivan D M, Wolmark N, McIntyre K, Jose Juan Ponce Lorenzo J J P, Filho O M, Rastogi P, Symmans W F, Liu X, Loibl S Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). J Clin Oncol 35, 2017 (suppl; abstr 520), ASCO 2017, Chicago

Kontakt

Hilal Gökgöz
Tel.: +4961027480-223
Fax: +4961027480-129
E-Mail: Pblctnsgbgd

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd